Yingke Private Equity

Yingke Private Equity

Yingke Private Equity was founded by Qian Mingfei and operates from its headquarters in Shanghai as a private equity firm. The firm has positioned itself as a research-intensive institution, with cumulative managed assets of approximately RMB 60 billion, sourced almost entirely from institutional investors including insurance companies and other large allocators. Yingke deploys capital across three core mandates: life sciences, dual-carbon technology, and hard-core technology. In life sciences, confirmed stage coverage ranges from venture to pre-IPO. Portfolio companies include Kanghua Biological (300841.SZ), a biologics firm commercializing a human diploid cell rabies vaccine, and Asieris Pharmaceuticals (688176.SH), which focuses on genitourinary oncology. The dual-carbon practice extends into new energy vehicles, photovoltaic manufacturing, and lithium-ion battery systems. Named assets include GAC Aion, a top-three Chinese new energy vehicle manufacturer by volume, and Zhuhai CosMX Battery (688772.SH), a consumer lithium-ion polymer battery supplier. Hard-core technology investments span semiconductor packaging, integrated circuits, and advanced connectors, with positions in companies such as China Wafer Level CSP (603005.SH), a pioneer in CMOS image sensor packaging, and CanSemi, a 12-inch wafer fabrication plant in Guangdong. The firm's geographic footprint concentrates on mainland China, particularly innovation clusters in the Yangtze River Delta and Greater Bay Area. The firm claims a portfolio of over 300 companies, with more than 60 exits or public listings. In August 2025, the firm announced portfolio company Haihe Biopharma's Japanese regulatory filing for a PI3Kα inhibitor, and Zhonghui Biotech's Hong Kong IPO, signaling continued late-stage momentum in its biopharma book. Yingke operates a “Golden Sycamore” industrial landing initiative and maintains a technology industry group entity, anchoring its model in industrial policy alignment and government-guided capital partnerships rather than a pure financial-sponsor approach. Yingke's architecture fuses direct principal investing with a managed-fund model leaning heavily on institutional limited partners. This structure—running a concentrated sector strategy while serving as a conduit for government-guided and state-backed capital into strategic industries—differentiates it from peer Chinese private equity firms that are more diversified or retail-funded. Qian Mingfei remains the central investment decision-maker, and the firm's communication emphasizes balance between financial returns and economic development mandates, a posture increasingly common among private equity managers navigating China's current regulatory environment.